CSL Behring - Recruiting N/A to 70 years. - A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B.
Pfizer - Recruiting 18 years to 64 years. - An Ascending Single Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics / Pharmacodynamics Of PF-05280602, A Recombinant Factor VIIa Variant (813d), In Adult Hemophilia A And B Subjects With Or Without Inhibitors.
Bayer - Recruiting N/A to 12 years. - A Multi-center, Phase III, Non-controlled, Open-label Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of BAY94-9027 for Prophylaxis and Treatment of Bleeding in Previously Treated Children (Age <12 Years) With Severe Hemophilia A.
Bayer - Recruiting 12 years to 65 years. - A Phase II/III, Multicenter, Partially Randomized, Open Label Trial Investigating Safety and Efficacy of On-demand and Prophylactic Treatment With BAY94-9027 in Severe Hemophilia A.
Karolinska University Hospital - Recruiting 10 years or older. - GLOBAL HEMOSTATIC METHODS IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE CORRELATION WITH PATIENTS' CLINICAL STATUS AND USEFULNESS FOR TREATMENT MONITORING.
CSL Behring - Recruiting N/A to 11 years. - A Multicentre, Interventional, Non-randomized, Open-label, Single-group Phase III Study to Evaluate Plasma-Derived Antihaemophilic Factor/Von Willebrand Factor Concentrate (Biostater) for Immune Tolerance Induction in Male Paediatric Subjects With Haemophilia A (ó 2%) Who Have Developed High-titre Antibodies to Factor VIII (Factor VIII Inhibitors).
Bayer - Recruiting N/A to 12 years. - A Multicenter Phase III Uncontrolled Open-label Trial to Evaluate Safety and Efficacy of BAY81-8973 in Children With Severe Hemophilia A Under Prophylaxis Therapy.
Bristol-Myers Squibb - Recruiting 18 years or older. - A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Nave or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin.
Pfizer - Recruiting N/A to 6 years. - An Open-Label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, And Pharmacokinetics (PK) Of B Domain Deleted Recombinant Factor VIII Albumin Free (Moroctocog Alfa [AF-CC]) In Children With Hemophilia A.
Pfizer - Recruiting N/A to 11 years. - A Non-Randomized, Open-Label Study To Evaluate The Pharmacokinetics, Safety, And Efficacy Of ReFacto AF In Previously Treated Pediatric Subjects Less Than Twelve Years Of Age With Severe Hemophilia A (FVIII:C <1%).
Bayer - Recruiting 18 years or older. - Evaluation of Efficacy, Safety and Costs of Recombinant FVIII Products Applied to Severe Hemophilia A Patients: Observational Data Collection Study Evaluating On-demand Treatment and Secondary Prophylaxis.
Alnylam Pharmaceuticals - Recruiting 18 years to 65 years. - A Phase 1 Single-ascending and Multiple-ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Subcutaneously Administered ALN-AT3SC in Healthy Adult Volunteers and Hemophilia A or B Patients (Moderate or Severe Hemophilia).
Baxter Healthcare Corporation - Recruiting 12 years to 65 years. - A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures.
CSL Behring - Recruiting 12 years to 65 years. - A Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Antihaemophilic Factor VIII (rFVIII; INN: Octocog Alfa) in Subjects With Hemophilia A, and a Repeat PK, Safety and Efficacy Study.
Green Cross Corporation - Recruiting 12 years or older. - Determination of Safety, Efficacy and Pharmacokinetics of GreenGeneT F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A.
GreenGeneT F and an approved recombinant Factor VIII product; GreenGeneT F
Spark Therapeutics, LLC - Recruiting 18 years or older. - A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX.
CSL Behring - Recruiting N/A to 11 years. - A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B.